Twist Bioscience (TWST) director awarded 5,095-share annual equity grant

Rhea-AI Filing Summary

Twist Bioscience director Robert Chess reported a stock grant and updated his holdings. On February 5, 2026, he received an annual equity award of 5,095 shares of common stock at a price of $0 per share, increasing his directly held shares to 23,268.

The award vests in full on the earlier of one year from grant or the first stockholder meeting after the grant, so long as he continues as a service provider. He also beneficially owns 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHESS ROBERT

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		5,095(1)	A	$0	23,268	D
Common Stock								42,528	I	By the Chess 1997 Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

2. The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert Chess	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Twist Bioscience (TWST) director Robert Chess report?

Director Robert Chess reported receiving 5,095 shares of Twist Bioscience common stock as an annual equity award on February 5, 2026. The shares were granted at $0 per share, increasing his directly held position to 23,268 shares after the transaction.

How many Twist Bioscience (TWST) shares does Robert Chess own after this Form 4?

After the reported grant, Robert Chess directly holds 23,268 Twist Bioscience common shares. He also beneficially owns 42,528 additional shares indirectly through the Chess 1997 Trust, where he and his spouse serve as sole trustees and beneficiaries under the trust arrangement.

What are the vesting terms of Robert Chess’s 5,095-share Twist Bioscience equity award?

The 5,095-share annual equity award will fully vest on the earlier of one year from the grant date or the first annual stockholder meeting after grant. Vesting requires that Mr. Chess continues as a non-employee director and service provider through each applicable vesting date.

How are Robert Chess’s indirect Twist Bioscience holdings structured?

Robert Chess’s indirect holdings consist of 42,528 Twist Bioscience shares held by the Chess 1997 Trust. He and his spouse are the sole trustees and sole beneficiaries of this trust, giving them beneficial ownership of these shares in addition to his directly held position.

Was there any cash paid for Robert Chess’s new Twist Bioscience shares?

No cash was paid for the new shares; the 5,095 Twist Bioscience shares were granted at a price of $0 per share. They represent an annual equity award for his service as a non-employee director, rather than an open-market purchase or sale transaction.